Last reviewed · How we verify
Levobupivacaine 25 mL
At a glance
| Generic name | Levobupivacaine 25 mL |
|---|---|
| Also known as | Chirocaine |
| Sponsor | Pontificia Universidad Catolica de Chile |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy (NA)
- Intrathecal Morphine Versus Epidural Analgesia for Open Colon Surgery (PHASE4)
- Intertransverse Process Block to Improve Quality of Recovery After Cardiac Surgery With Sternotomy (NA)
- The Immune Response of Breast Cancer Patients Treated With Levobupivacaine Using Paravertebral or Superficial Chest Blocks (NA)
- Intrathecal Morphine Versus Epidural Analgesia for Laparoscopic Colon Surgery (PHASE4)
- Dexmeditomedine as an Adjuvant to Levobupivacaine in Transversus Thoracis Plane Block on the Management of Post-sternotomy Pain in Open-heart Surgeries (NA)
- Study Comparing Dural Puncture Epidural With Epidural and Combined Spinal Epidural Anesthesia for Obstetric Analgesia. (PHASE3)
- Comparison of Intratechal Levobupivacaine and Adding With Sufetanil and Fentanyl in Ceserean Section (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levobupivacaine 25 mL CI brief — competitive landscape report
- Levobupivacaine 25 mL updates RSS · CI watch RSS
- Pontificia Universidad Catolica de Chile portfolio CI